The Impact of Frailty on Cardiopulmonary Resuscitation Adverse Outcomes in Patients Requiring Code Blue Activation
Launched by UMRANIYE EDUCATION AND RESEARCH HOSPITAL · May 6, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how frailty, or weakness and decreased strength, affects the outcomes of patients who experience a cardiac or respiratory arrest and require emergency resuscitation (commonly known as a "code blue"). The researchers want to understand if being frail makes a difference in how well patients respond to CPR and what other factors might be important in these situations.
The trial is currently recruiting participants, including children aged 6 to 24 years. Unfortunately, pregnant individuals are not eligible to join the study. If you or a family member participate, you will help researchers gather important information that could improve emergency care for future patients. Overall, this study aims to shed light on how frailty impacts emergency medical responses, which could lead to better treatment strategies for those in need.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • pediatric patients
- Exclusion Criteria:
- • pregnant patients
About Umraniye Education And Research Hospital
Umraniye Education and Research Hospital is a leading healthcare institution dedicated to advancing medical research and education. Located in Istanbul, Turkey, the hospital is renowned for its commitment to providing high-quality patient care while fostering innovation in clinical trials. As a clinical trial sponsor, Umraniye Education and Research Hospital emphasizes ethical standards, rigorous scientific methodology, and collaboration with healthcare professionals and researchers. The institution aims to contribute to the development of new therapies and improve health outcomes through its robust research programs and a multidisciplinary approach to clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported